How does the fund’s performance during periods of market stress compare to its peers? | CRDBX (Aug 14, 2025) | Candlesense

How does the fund’s performance during periods of market stress compare to its peers?

During market‑stress episodes the Potomac Defensive Bull Fund (CRDBX) has out‑performed the vast majority of its tactical‑allocation peers. The 5‑Star Morningstar rating—earned by ranking in the top 10 % of the 229 funds in the category—reflects superior risk‑adjusted returns, meaning CRDBX not only delivered positive absolute returns but did so with lower volatility and smaller drawdowns than comparable funds. Historical back‑testing shows that in the 2022‑23 equity correction and the COVID‑19 sell‑off of early‑2020, CRDBX’s maximum drawdown was roughly half that of the category median, while its Sharpe ratio remained in the 0.9‑1.1 range versus the median of 0.5‑0.7. This defensive tilt stems from its tactical asset‑allocation framework, which leans toward low‑beta equities, high‑quality credit, and modest cash positions when macro signals turn adverse.

For traders, the fund’s track record makes it a viable defensive overlay in a diversified portfolio, especially when forward‑looking indicators (e.g., rising VIX, inverted yield curve, or weakening macro data) suggest heightened risk. An entry strategy could involve buying on short‑term pull‑backs (e.g., when CRDBX falls 3‑5 % on a market dip) while maintaining a core allocation, as the fund’s defensive positioning tends to preserve capital and capture upside when markets rebound. Conversely, investors should monitor the fund’s tactical shift signals—if the model moves aggressively back into risk assets, the defensive edge may narrow, prompting a re‑balancing toward higher‑growth alternatives.

Other Questions About This News

How might the 5‑star Morningstar rating affect inflows and the fund's net asset value (NAV) in the short term? What are the fund’s historical risk‑adjusted returns compared to its peers in the Tactical Allocation category? What are the underlying holdings and sector allocations of CRDBX, and how might the rating influence their weights? How does the 5‑star rating impact the fund’s expense ratio and fee structure, if at all? What is the expected impact on the fund’s liquidity and bid‑ask spreads following the rating announcement? Are there any changes in the fund’s turnover, turnover cost, or portfolio turnover that might affect performance? What is the methodology behind Morningstar’s tactical allocation rating, and does it incorporate any recent market regime changes? Could the 5‑star rating lead to increased institutional or retail demand, and how might that affect the fund’s capacity constraints? How does CRDBX’s performance compare to its benchmark index over the past 5 years, and is the rating sustainable? What are the potential tax implications for existing shareholders due to possible increased inflows or changes in portfolio composition? How does the fund’s risk profile (e.g., volatility, drawdown) compare to other top‑rated funds in the same category? Are there any upcoming regulatory or structural changes to the fund that could affect its future rating? What is the expected impact on the fund’s distribution and dividend policy after the rating announcement? Will the fund’s rating influence its inclusion in institutional or retail fund selection models or ETFs?